PATENT CLAIM ANALYSIS

Application Number: 16056613
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-11
Patent Classification: ["424", "465000"]

Abstract:
Solid pharmaceutical dosage form for the release of at least one Active Pharmaceutical Ingredient (API) in the oral cavity comprising a core coated by at least one film coating. The core comprises at least one API. One or more organoleptically disturbing sensations induced by one or several of the APIs and/or of inactive components of the solid pharmaceutical dosage form is/are reduced by constituents of said film coating. Said constituents comprise at least one film-forming polymer and at least one flavoring agent or at least one sweetener.

Claim (Index 28):
The method of administering a lozenge according to  claim 27 , wherein the API is selected from the group consisting of benzocaine, dyclonine, lidocaine, benzydamine, flurbiprofen, paracetamol, chlorhexidine, phenylephrine, acetylcysteine, ambroxol, bromhexin, domiodol, eprazinon, etosteine, stepronin, zinc salts, guaifenesin, dropropizine and dextromethorphan.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 96.0
- Lexical Diversity: 1.69091
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12057177', '11223819', '15879740', '15387317', '15852486']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7778489630894209
- 35 USC 102 Novelty (BERT): 0.4987060798100141
- Combined Prediction Score: 0.7499346747614802
- Mean Citation Score: 222.17800400000004
- Max Citation Score: 235.37862
- Similarity Product: 158.86481599883797

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test